Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger L Nation

Showing results (61-70 of 247) with videos related to

Pageof 25
Sort By:
Future Microbiology|May 25, 2013
Pharmacology of polymyxins: new insights into an 'old' class of antibioticsTony Velkov, Kade D Roberts, Roger L Nation, et al.
Antimicrobial Agents and Chemotherapy|October 11, 2017
Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing SchemesRajbharan Yadav, Jürgen B Bulitta, Jiping Wang, et al.
International Journal of Antimicrobial Agents|December 29, 2004
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaJian Li, Roger L Nation, Robert W Milne, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2011
Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokineticsJumana M Yousef, Gong Chen, Prue A Hill, et al.
American Journal of Pharmaceutical Education|April 24, 2010
A palliative cancer care flexible education program for Australian community pharmacistsSafeera Yasmeen Hussainy, Jennifer L Marriott, Jill Beattie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2007
Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strainsJian Li, Roger L Nation, Roxanne J Owen, et al.
Journal of Pharmaceutical Sciences|May 25, 2012
Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulationStephanie J Wallace, Jian Li, Roger L Nation, et al.
Infectious Disease Clinics of North America|May 22, 2016
Agents of Last Resort: Polymyxin ResistanceKeith S Kaye, Jason M Pogue, Thien B Tran, et al.
Pharmaceutics|September 25, 2019
Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based ModellingVanessa E Rees, Jürgen B Bulitta, Antonio Oliver, et al.
ACS Pharmacology & Translational Science|June 23, 2020
Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic SurgeryCornelia B Landersdorfer, Martina Kinzig, Rainer Höhl, et al.
Pageof 25

Showing results (61-70 of 247) with videos related to

Sort By:
Pageof 25
Future Microbiology|May 25, 2013
Pharmacology of polymyxins: new insights into an 'old' class of antibioticsTony Velkov, Kade D Roberts, Roger L Nation, et al.
Antimicrobial Agents and Chemotherapy|October 11, 2017
Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing SchemesRajbharan Yadav, Jürgen B Bulitta, Jiping Wang, et al.
International Journal of Antimicrobial Agents|December 29, 2004
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaJian Li, Roger L Nation, Robert W Milne, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2011
Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokineticsJumana M Yousef, Gong Chen, Prue A Hill, et al.
American Journal of Pharmaceutical Education|April 24, 2010
A palliative cancer care flexible education program for Australian community pharmacistsSafeera Yasmeen Hussainy, Jennifer L Marriott, Jill Beattie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2007
Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strainsJian Li, Roger L Nation, Roxanne J Owen, et al.
Journal of Pharmaceutical Sciences|May 25, 2012
Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulationStephanie J Wallace, Jian Li, Roger L Nation, et al.
Infectious Disease Clinics of North America|May 22, 2016
Agents of Last Resort: Polymyxin ResistanceKeith S Kaye, Jason M Pogue, Thien B Tran, et al.
Pharmaceutics|September 25, 2019
Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based ModellingVanessa E Rees, Jürgen B Bulitta, Antonio Oliver, et al.
ACS Pharmacology & Translational Science|June 23, 2020
Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic SurgeryCornelia B Landersdorfer, Martina Kinzig, Rainer Höhl, et al.
Pageof 25